SEC Form 4 · accession 0000899243-18-020988
Aldeyra Therapeutics, Inc. · ALDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joshua Reed
Officer — Chief Financial Officer
Period of report
Jul 30, 2018
Accepted (ET)
Aug 1, 2018 · 4:46 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001341235
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $6.80 | Jul 30, 2018 | A | 75,000 | A | — | Jul 29, 2028 | Common Stock | 75,000 | 75,000 | D |
Explanation of responses
- F125% of the shares subject to this option shall vest after one year of continuous service to the Issuer. The balance of the shares subject to this option shall vest in equal monthly installments over the next 36 months of continuous service to the Issuer following the vesting commencement date.